A Clinical Study of Polatuzumab Vedotin-Based Combination Regimen for Low-Risk Large B-Cell Lymphoma (ChiCTR) - Oct 16, 2026 - P2 | N=50 | Not yet recruiting | Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
New P2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CD20
|